Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment